This chapter tells the largely untold story of the political economy of international drug regulation in the 1950s. It will tell the story of producer country efforts, led by Turkey, Iran and India, to agree an international quota system for opium and thus to divide up the licit global market. It examines the simultaneous efforts to suppress the global illicit market and minimise the numbers of producers to a small select few who would enjoy an enforced oligopoly. It highlights the quiet diplomatic pressure placed on countries viewed as epicentres of the global trade and a conscious ignorance of strategically important states – for example the US State Department refusing to criticise French Indochina and Mexico. Further, it tells the story of Harry Anslinger’s efforts to incorrectly portray Communist China as the world’s leading narcostate. It concludes with a look at the breakdown of multilateralism over the 1953 Opium Protocol, a treaty which few accepted but was rammed through by the US and some select allies. It was this Protocol which ultimately galvanised moderates and producer states around the need for a Single Convention to roll back the excesses of the 1953 Protocol.

This chapter examines the legal legal of the Single Convention and its successor treaties. The passage of the Single Convention represented a high-water mark in the international regulatory system. While it contained little in terms of innovation, it streamlined the complex array of drug treaties, while moving the terrain of control forward marginally. It essentially solidified an economic regulatory framework for a global licit commodity market in certain essential medicines. To enforce this market it mandated certain action around controlling and prohibiting non-medical production and manufacturing. Key questions around dealing with ‘addiction’ and suppressing non-medical consumption were left largely unanswered. The US may have lost the battle around the Single Convention and control of the system in the 1960s but they would enter the 1970s ready to refight many of these battles, beginning with the declaration of the ‘war of drugs’ and an aggressive new round of bilateral drug diplomacy. Ultimately the ‘war on drugs’ was not an inevitable outgrowth of these documents, but instead represented a specific set of interpretations, bureaucratic and normative trajectories and member state implementations.

This chapter argues that whereas much of the past century was geared towards a legal and institutional homogenisation of international drug control, the coming decades appear underpinned by recourse to ‘policy pluralism’ as a mechanism to enable policy evolution. It is precisely these endogenous processes of pluralism, devolution and increasing diversity of global drug policies that provide the most promising avenues for various actors to influence policies at local, national, regional and international levels. It further argues that the international drug control system is undergoing a long-term process of fragmentation and evolution towards what international relations scholars in other spheres would term a ‘regime complex’. It concludes by suggesting that these endogenous regime changes likely provide the greatest opportunity to draw exogenous actors and regimes into the system’s orbit and thereby modernise and adapt drug policies to new global realities.

This chapter examines the creation of the 1961 UN Single Convention on Narcotic Drugs. It was also a period when transatlantic relations reached a new low in drug diplomacy. Minor cooperation in the aftermath of the 1953 Opium Conference gave way to divisions leading to an eventual rupture over the Single Convention, particularly between Britain and the US. This breakdown was ultimately was the result of failures of US leadership as well as deep divisions over policy and economic interests. The US found itself increasingly alone in negotiations. State Department leadership sought a more conciliatory approach towards producers like Iran and Afghanistan. Nevertheless, with Anslinger increasingly absent and with a lack of institutional knowledge within the State Department US delegations struggled to develop a US grand strategy. Britain, continuing to carve out a role of quiet, consensual and self-interested drug diplomacy, found the new environment conducive and became increasingly assertive. London pragmatically worked with shifting coalitions, while building a moderate bloc of manufacturing states in Europe to help protect British domestic interests via the Single Convention. The result was a consensus-based treaty and one largely rejected by the US, which tried and failed to torpedo the treaty.